BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
Sihuan Pharma’s Botox Beauty Bid Suffers Covid Wrinkle
The cardiovascular and cancer drug maker’s recent shift to the medical beauty business was doing well at first, but struggled last yearKey Takeaways:Sihuan Pharmaceutical’s recent move into the medical beauty…
Recent Articles
RELATED ARTICLES
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG -
FAST NEWS: Beigene stock falls after Novartis terminates partnership
BGNE.US 6160.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
